Osteosarcoma Therapeutics Market Pipeline Review, H2 2017
“Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma -
Pipeline Review, H2 2017, provides an overview of the Osteosarcoma
(Oncology) pipeline landscape.”
Summary
Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides an
overview of the Osteosarcoma (Oncology) pipeline landscape.
Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is
developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone
fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history
and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review,
H2 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma
(Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type.
Browse Detail Report With TOC @
https://www.hexareports.com/report/osteosarcoma-pipeline-review-h2-2017
Follow Us: